DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,015 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,803,167 | +0.1% | 7,217 | 0.0% | 0.24% | -0.4% |
Q1 2024 | $1,802,229 | +21.3% | 7,217 | +12.4% | 0.24% | +22.6% |
Q4 2023 | $1,485,665 | -35.9% | 6,422 | -31.2% | 0.20% | -41.6% |
Q3 2023 | $2,317,502 | -1.4% | 9,341 | -4.6% | 0.34% | +4.0% |
Q2 2023 | $2,349,840 | -6.0% | 9,791 | -1.3% | 0.33% | -12.3% |
Q1 2023 | $2,500,993 | -0.6% | 9,923 | +4.6% | 0.37% | -4.1% |
Q4 2022 | $2,517,243 | +12.3% | 9,484 | +9.3% | 0.39% | +14.0% |
Q3 2022 | $2,241,000 | -3.2% | 8,676 | -5.0% | 0.34% | +4.0% |
Q2 2022 | $2,315,000 | -13.6% | 9,130 | -0.1% | 0.33% | +13.8% |
Q1 2022 | $2,680,000 | -7.2% | 9,137 | +4.1% | 0.29% | +0.3% |
Q4 2021 | $2,888,000 | +19.3% | 8,779 | +10.4% | 0.29% | +30.9% |
Q3 2021 | $2,421,000 | +26.6% | 7,951 | +11.6% | 0.22% | +27.9% |
Q2 2021 | $1,912,000 | +19.3% | 7,123 | 0.0% | 0.17% | +14.7% |
Q1 2021 | $1,603,000 | +13.3% | 7,123 | +11.8% | 0.15% | +9.5% |
Q4 2020 | $1,415,000 | +4.5% | 6,369 | +1.3% | 0.14% | -14.9% |
Q3 2020 | $1,354,000 | +22.3% | 6,289 | +0.5% | 0.16% | +12.6% |
Q2 2020 | $1,107,000 | -10.0% | 6,259 | -29.6% | 0.14% | -34.1% |
Q1 2020 | $1,230,000 | -14.3% | 8,886 | -5.0% | 0.22% | +13.0% |
Q4 2019 | $1,435,000 | +6.9% | 9,350 | +0.5% | 0.19% | -1.0% |
Q3 2019 | $1,343,000 | -5.8% | 9,300 | -6.7% | 0.19% | +1.6% |
Q2 2019 | $1,425,000 | +8.3% | 9,970 | 0.0% | 0.19% | -0.5% |
Q1 2019 | $1,316,000 | +15.3% | 9,970 | -9.9% | 0.19% | +2.7% |
Q4 2018 | $1,141,000 | -5.1% | 11,060 | 0.0% | 0.19% | +29.0% |
Q3 2018 | $1,202,000 | +18.1% | 11,060 | +7.2% | 0.14% | +8.2% |
Q2 2018 | $1,018,000 | +2.0% | 10,320 | +1.3% | 0.13% | -10.7% |
Q1 2018 | $998,000 | +121.8% | 10,190 | +110.0% | 0.15% | +114.3% |
Q4 2017 | $450,000 | +8.2% | 4,852 | 0.0% | 0.07% | +4.5% |
Q3 2017 | $416,000 | -0.2% | 4,852 | -1.8% | 0.07% | -8.2% |
Q2 2017 | $417,000 | 0.0% | 4,942 | +1.4% | 0.07% | -8.8% |
Q1 2017 | $417,000 | +12.1% | 4,872 | +1.9% | 0.08% | +6.7% |
Q4 2016 | $372,000 | +3.3% | 4,780 | +4.2% | 0.08% | +1.4% |
Q3 2016 | $360,000 | -18.0% | 4,587 | +5.4% | 0.07% | -24.5% |
Q2 2016 | $439,000 | -3.7% | 4,351 | -9.6% | 0.10% | -9.3% |
Q1 2016 | $456,000 | -1.3% | 4,811 | -3.2% | 0.11% | -0.9% |
Q4 2015 | $462,000 | -73.6% | 4,970 | -75.8% | 0.11% | -73.5% |
Q3 2015 | $1,753,000 | -50.1% | 20,570 | -49.8% | 0.41% | +7.0% |
Q2 2015 | $3,510,000 | +101.7% | 41,000 | +100.0% | 0.38% | +8.2% |
Q1 2015 | $1,740,000 | -1.0% | 20,500 | 0.0% | 0.36% | +1.4% |
Q4 2014 | $1,757,000 | – | 20,500 | – | 0.35% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |